All Projects

CeNeReg

Antibodies against Nogo-A to enhance regeneration of the injured central nervous system

Wysszurich keyvisual cenereg

Potential

CeNeReg's goal is to enhance long-term axonal regeneration in the injured central nervous system and improve functional recovery.

Project Description

Nerve fibers in the adult central nervous system (i.e., the spinal cord and brain) fail to regenerate after injury, and to date there are no therapies for enhancing their repair. Spinal cord injuries have dramatic and long-term effects on people’s lives, and the social and economic burdens of lifelong care are enormous.

For a long time, it was generally believed that damaged fiber tracts of the central nervous system were incapable of regeneration. However, there is growing evidence that specific inhibitory molecules found in myelin (i.e. the protective layer surrounding the nerve fibers) prevent nerve fiber regeneration and are the cause of poor functional recovery after injury. This explanation was first proposed by Professor Martin Schwab and his group at the University of Zurich; they also discovered the most potent growth inhibitor that has been identified so far: the membrane protein Nogo-A. Moreover, Schwab and his team demonstrated that antibodies blocking the function of Nogo-A lead to long-distance regeneration of injured nerve fibers in the spinal cord of monkeys and rats and greatly improve the animals’ functional recovery.

With the support of Wyss Zurich’s Regenerative Medicine Technologies Platform, the team manufactured the final drug product to enable a clinical trial to test the efficacy of antibodies against Nogo-A in patients with spinal cord injury. The antibody enabled the critical transition to Phase II clinical trials, intended to demonstrate the clinical efficacy of the anti-Nogo-A antibody in patients with spinal cord injuries.

Beyond the field of spinal cord injury, these clinical studies served as a model for other conditions in which the nerve fibers of the central nervous system have been injured and may, therefore, have a substantial impact on the treatment of neurological diseases in general. A positive outcome of the clinical trials would constitute a major breakthrough in the fields of neurology, neuroscience, and tissue regeneration and repair.

Contact

NovaGo Therapeutics AG
info@novagotx.com

Contact

Bettina Steiner

Bettina steiner portrait

Faculty Mentor

Martin Schwab

Portrait Ce Ne Reg mentor schwab 560

Partners and Funding

  • Co-funded by the EU Horizon 2020
  • European Research Council
  • Swiss National Science Foundation
  • Christopher & Dana Reeve Foundation

Achievements

12/2022
Wyss Zurich project completion

The project CeNeReg exits Wyss Zurich 

07/2022
CT Phase II recruitment complete

The recruitment of patients for the clinical trial is completed

04/2019
Start Clinical Trial Phase II

Swiss clinical sites are ready to enroll first patients in the Phase II clinical study.

03/2019
Completed Series A Funding

NovaGo Therapeutics closes a Series A financing round of CHF 10 million.

02/2016
Wyss Zurich Admission

CeNeReg is accepted as a full project.

03/2015
NovaGo Therapeutics AG incorporation

Incorporation of the biotech company NovaGo Therapeutics AG.

Core Team

Bettina steiner portrait

Bettina Steiner

Project Leader

Do you have a breakthrough project you want us to know about?

We urge you to contact the Wyss Zurich office to discuss your project and start the evaluation process.